NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
Clinical Trials
579 trialsNCT05189366 2026-04-14
SOPHNEURO
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT03398915 2026-03-31
EUROSPIN
Bergman Clinics
Active not recruiting
NCT02455557 2026-03-30
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT01743950 2026-03-25
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
NCT03197506 2026-03-25
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
Phase 2 Active not recruiting
NCT04545814 2026-03-24
Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases
Medical College of Wisconsin
Phase NA Completed
NCT02852655 2026-03-20
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT03475186 2026-03-13
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04283669 2026-03-13
NF110
University of Alabama at Birmingham
Phase 2 Completed
NCT02858869 2026-03-09
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
Phase 1 Completed
NCT04268979 2026-02-20
Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT03450850 2026-02-17
Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
University of California, Irvine
Phase NA Completed
NCT03405792 2026-02-06
2-THE-TOP
University of Florida
Phase 2 Active not recruiting
NCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03279692 2026-01-29
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02648997 2026-01-26
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04825275 2026-01-23
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Terminated
NCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT00602667 2026-01-13
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02282917 2025-12-05
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
Phase EARLY_PHASE1 Terminated
NCT03687957 2025-11-25
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT02192359 2025-11-14
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02939300 2025-11-14
Ipilimumab and Nivolumab in Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Completed
NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
NCT04209790 2025-11-10
NeoGlio
Geisinger Clinic
Phase 2 Terminated
NCT03412812 2025-11-04
RAD1705
University of Alabama at Birmingham
Phase NA Completed
NCT02162732 2025-11-03
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Phase NA Completed
NCT03557359 2025-11-03
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
Phase 2 Completed
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT04424966 2025-10-24
Infigratinib in Recurrent High-Grade Glioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Terminated
NCT03868943 2025-10-21
JAZZ
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01991977 2025-10-20
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT03076255 2025-10-15
Using a Head and Neck Maskless Immobilization Device For Patients With Intracranial Tumors
Thomas Jefferson University
Phase NA Completed
NCT02285439 2025-10-07
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
Phase 1/2 Completed
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02062827 2025-10-02
M032-HSV-1
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02208362 2025-09-03
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02981940 2025-09-02
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02603328 2025-08-22
AT CASH EPOC
University of Chicago
Phase 1/2 Completed
NCT02337686 2025-08-15
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04225039 2025-08-15
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
University of Pennsylvania
Phase 2 Active not recruiting
NCT01063114 2025-08-13
Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
Massachusetts General Hospital
Phase NA Completed
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed